Compass veers off course, delaying phase 3 psychedelic data and laying off 30% of staff
Compass will part ways with approximately 30% of its workforce, including some management positions… one year ago, the company expected to have data from the first phase 3 trial of its COMP360 psilocybin therapy in treatment-resistant depression by the summer of 2024. Compass CEO Kabir Nath framed that delay in the context of the FDA’s rejection of…
Recent Comments